A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


December 10, 2012

HIV Docs Believe Meds Prevent Transmission, But Don’t Start ARVs Early

HIV clinicians widely believe in the antiretroviral (ARV) treatment as prevention model, but they don’t necessarily apply the concept to individual patients, with only one in seven clinicians immediately starting treatment in patients, a new study has found. Published in the recent issue of the Journal of Acquired Immune Deficiency Syndromes, the paper examined the AVR-prescribing patterns and attitudes about treatment initiation among 38 health care providers in the Bronx, New York, and Washington, DC—a sample that the researchers felt might be comparable with other urban clinicians across the country.

Polling 165 physicians, nurse practitioners and physician assistants through an Internet-based survey, the research team from New York University, Fenway Health, Harvard, and other research groups found that 95 percent “strongly agreed” or “agreed” that early initiation of ARVs can lower transmission rates. Similar to the 55 percent of the Department of Health and Human Services guideline panel that in 2010 recommended beginning HIV therapy when CD4 counts drop below 500, 56 percent of the HIV clinicians polled favored starting therapy at CD4 levels between 350 and 500.

Meanwhile, only 14 percent encouraged patients to begin therapy immediately, regardless of CD4 counts. However, 75 percent recommended early therapy for patients in serodiscordant relationships, and 40 percent did so for those having unprotected sex with a partner with an unknown HIV status.

“There remains an inherent tension in prescribing [ARVs] to individuals for a population-benefit,” the researchers write, “when the risk-benefit profiles of multidecades-long treatment are not yet available. Nonetheless, there is emerging evidence that [ARV] initiation at higher [CD4] counts may have individual benefit.”

The paper goes on to say that, “Our findings suggest that clinicians will need to continue to balance emerging information regarding efficacy of [ARV] for prevention with their duty to provide patients with interventions that have a favorable long-term benefit to their own health.”

To read the study’s abstract, click here.

Search: HIV, treatment as prevention, antiretroviral, ARV, clinician, begin, Journal of Acquired Immune Deficiency Syndromes, Bronx, New York, Washington, DC, New York University, Fenway Health, Harvard, Department of Health and Human Services, guideline panel, serodiscordant relationships, unprotected sex.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.